Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme[J]. Biochem Biophys Res Commun, 1963, 11(1): 39-43.
[2]
Bai P, Bakondi E, Szabo EE, et al. Partial protection by poly(ADP-ribose) polymerase inhibitors from nitroxyl-induced cytotoxity in thymocytes[J]. Free Radic Biol Med, 2001, 31:1 616-1 623.
[3]
Burkle A. Physiology and pathophysiology of poly(ADP-ribosyl)ation[J]. Bioessays, 2001, 23: 795-806.
[4]
Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1, what have we learned from the deficient mouse model[J]. Mutat Res, 2000, 460: 1-15.
[5]
Kim MY, Mauro S, Gervy N, et al. NAD+ dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1[J]. Cell, 2004, 119: 803-814.
[6]
Kim MY, Zhang T, Kraus WL. Poly(ADPribosyl)ation by PARP-1: PAR-laying NAD+ into a nuclear signal[J]. Genes Dev, 2005, 19: 1 951-1 967.
[7]
Schreiber V, Danter F, Ame JC, et al. Poly(ADP-ribose): novel functions for an old molecule[J]. Nat Rev Mol Cell Biol, 2006, 7: 517-528.
[8]
Saxena A, Saffery R, Wong LH, et al. Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated[J]. J Biol Chem, 2002, 277: 26 921-26 926.
[9]
Samper E, Goytisolo FA, Menissier de Murcia J, et al. Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability[J]. J Cell Biol, 2001, 154: 49-60.
[10]
Burkle A. Poly(ADP-ribose): the most elaborate metabolite of NAD+[J]. FEBS J, 2005, 44: 4 576-4 589.
[11]
Sodhi RK, Nirmal Singh, Jaggi AS. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications[J]. Vascular Pharmacology, 2010, 53: 77-87.
[12]
Alvarez Gonzalez R, Pacheco Rodriguez G, Mendoza Alvarez H. Eazymology of ADP-ribose polymer synthesis[J]. Mol Cell Biochem, 1994, 138(1-2): 33-37．
[13]
Ame JC, Spenlehauer C, de Murica G. The PARP superfamily[J]. Bioessays, 2004, 26: 882-893.
[14]
Berger NA. Poly(ADP-ribose)in the cellular response to DNA damage[J]. Radiat Res, 1985, 101(1): 4-15.
[15]
Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose)polymerase inhibitors[J]. 2002, 54: 375-429.
[16]
Nozaki T, Fujihara H, Watanabe M, et al. Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane[J]. Cancer Sci, 2003, 94: 497-500.
[17]
Nozaki T, Fujihara H, Watanabe M, et al. Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane[J]. Cancer Sci, 2003, 94: 497-500.
[18]
Tsutsumi M, Masutani M, Nozaki T, et al. Increased susceptibility of poly(ADPribose) polymerase-1 knockout mice to nitrosamine carcinogenicity[J]. Carcinogenesis, 2001, 22: 1-3.
[19]
Conde C, Mark M, Oliver FJ, et al. Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53deficient mice[J]. EMBO J, 2001, 20: 3 535-3 543.
[20]
Calabrese CR, Batey MA, Thomas HD, et al. Identification of potent nontoxic poly(ADP-ribose)polymerase-1 inhibitors: chemopotentiation and pharmacological studies[J]. Clin Cancer Res, 2003, 9: 2 711-2 718.
[21]
Miki K, Uehara N, Shikata N, et a1．Poly(ADP-ribose)polymerase inhibitor 3-aminobenzamide rescues N-methyl-N-nitrosourea induced photoreceptor cell apoptosis in spraguedawley rats through preservation of nuclear factor—kappaB activity[J]．Exp Eye Res, 2007, 84, 2：285-292．
[22]
Rose JL, Reeves KC, Likhotvorik RI, et al．Base excision repair proteins are required for integrin-mediated suppression of bleomycin-induced DNA breakage in murine lung endothelial cells[J]. J Pharmacol Exp Ther, 2007, 321, 1: 318-326．
[23]
Thomas HD, Calabrese CR, Batey MA, et a1. Preclinicel selection of a novel poly( ADP-ribose)polymerase inhibitor for clinical trial[J]. Mol Cancer Ther, 2007, 6（3）: 945-956.
[24]
Dungey FA, Lser DA, Chalmeers AJ. Replication-dependent radio-sensitization of human glioma cells by inhibition of poly(ADP-ribose)polymerase：mechanisms and therapeutic potential[J]. Int J Radiat Oncol Biol Phys, 2008, 72, 4: 1 188-1 197.
[25]
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J]. Nature, 2005, 434: 917-921.
[26]
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2 deficient tumours with inhibitors of poly(ADP-ribose)polymerase[J]. Nature, 2005, 434: 913-917.
Gabriele Costantino, Antonio Macchiarulo, Emidio Camaioni, et al. Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors: Docking of ligands and quantitative structure-activity relationship analysis[J]. J Med Chem, 2001, 44: 3 786-3 794.
[29]
Watson CY, Whishb WJD, Threadgill MD. Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP) [J]. Bioorg Med Chem, 1998, 6: 721-734.
[30]
Clark JB, Ferris JM, Pinder S. Control of nucleic acid and nicotinamide nucleotide synthesis in generating rat liver[J]. Bichem Biophys Acta, 1971, 238: 82-87.
[31]
Cosi C. New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets[J]. Expert Opin Ther Patents, 2002, 12: 1 047-1 071.
[32]
Watson CY, Whish WJ, Threadgill MD. Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)[J]. Bio Org Med Chem, 1998, 6: 721-734.
[33]
Bowes J, McDonald MC, Piper J, et al. Inhibitors of poly(ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress[J]. Cardiovasc Res, 1999, 41: 126-134.
[34]
Liaudet L, Szabo E, Timashpolsky L, et al. Suppression of poly(ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction, long-term morphological and functional consequences[J]. Br J Pharmacol, 2001, 133: 1 424-1 430.
[35]
Liaudet L, Szabo A, Soriano FG, et al. Poly(ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia[J]. Shock, 2000, 14: 134-141.
[36]
Cuzzocrea S, Zingarelli B, Costantino G, et al. Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion[J]. Br J Pharmacol, 1997, 121: 1 065-1 074.
[37]
Chatterjee PK, Cuzzocrea S, Thiemermann C. Inhibitors of poly(ADP-ribose) synthetase protect rat proximal tubular cells against oxidant stress[J]. Kidney Int, 1999, 56: 973-984.
[38]
Thiemermann C, Bowes J, Myint F, et al. Inhibition of the activity of poly(ADP-ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle[J]. Proc Nat Acad Sci, 1997, 94: 679-683.
[39]
Griffin RJ, Curtin NJ, Newell DR, et al. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy[J]. Biochimie, 1995, 77: 408-422.
[40]
Watson CY, William JDW, Threadgill MD. Threadgill: synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)[J]. Bioorg Med Chem, 1998, 6: 721-734.
[41]
Li Hong, Goldstein BM. Carboxamide group conformation in the icotinamide and thiazole-4-carboxamide rings: implications for enzyme binding[J]. J Med Chem, 1992, 35: 3 560-3 567.
Banasik M, Komura H, Shimoyama M, et al. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase[J]. J Biol Chem, 1992, 267: 1 569-1 575.
[44]
Suto MJ, Turner WR, Werbel LM, et al. Dihyrdroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose)polymerase[J]. Anticancer Drug Dev, 1991, 6: 107-117.
[45]
Southan GJ, Szabo C. Poly(ADPribose)polymerase inhibitors[J]. Curr Med Chem, 2003, 10: 321-340.
[46]
Docherty JC, Kuzio B, Silvester JA, et al. An inhibitor of poly(ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levelsduring reperfusion of the ischaemic rat heart[J]. Br J Pharmacol, 1999, 127: 1 518-1 524.
[47]
McDonald MC, Mota-Filipe H, Wright JA, et al. Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly(ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock[J]. Br J Pharmacol, 2001, 130: 843-850.
[48]
Wayman N, McDonald MC, Thompson AS, et al. 5-Aminoisoquinolinone, a potent inhibitor of poly(adenosine 5’-diphosphateribose) polymerase, reduces myocardial infarct size[J]. Eur J Pharmacol, 2001, 430: 93-100.
[49]
Shinkwin AE, William JDW, Threadgill MD. Synthesis of thioph-enecarboxamides, thieno[3,4-c]pyridin-4(5H)-ones and thieno[3,4-d]pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)[J]. Bioorg Med Chem, 1999, 7: 297-308.
[50]
Canan Koch SS, Thoresen LH, Tikhe JG, et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure[J]. J Med Chem, 2002, 45: 4 961-4 974.
[51]
Plummer R, Jones C, Middleton M, et al. Phase Ⅰ study of the poly(ADP-ribose)polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors[J]. Clin Cancer Res, 2008, 14: 7 917-7 923.
[52]
Penning TD, Zhu GD, Gandhi VB, et al． Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose)polymerase(PARP) for the treatment of cancer[J]. Bioorg Med Chem, 2008, 16, 14: 6 965-6 975．
[53]
Penning TD, Zhu GD, Gandhi VB, et al. Discovery of the poly(ADP-ribose)polymerase(PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide(ABT-888) for the treatment of cancer[J]. J Med Chem, 2009, 2(2): 514-523．
[54]
Donawho CK, Luo Y, Luo YP, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models[J]. Clin Cancer Res, 2007, 13: 2 728-2 737.
[55]
Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology[J]. Expert Opin Investig Drugs, 2009, 18(1): 31-43．
[56]
Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors from concept to clinic[J]. J Med Chem, 2010, 53: 4 561-4 584.
[57]
Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly( ADP-ribose) polymerase inhibitor that potentiates DNAdamaging agents in preclinical tumor models[J]. Clin Cancer Res, 2007, 13(9): 2 728-2 737.
[58]
Fauzee NJ， PAN J，Wang YL．PARP and PARG inhibitors: New therapeutic targets in cancer treatment[J]. Pathol Oncol Res, 16, 4: 469-478.
[59]
Delaney CA, Green MH, Lowe JE, et al. Endogenous nitric oxide induced by interleukin-1 beta in rat islets of Langerhans and HIT-T15 cells causes significant DNA damage as measured by the “comet” assay[J]. FEBS Lett, 1993, 333: 291-295.
[60]
White AW, Almassy R, Calvert AH, et al. Resistance-modifying agents: Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase[J]. J Med Chem, 2000, 43: 4 084-4 097.
[61]
Cepeda V, Fuertes MA, Castilla J, et al．Poly(ADP-ribose)polymerase-1(PARP-1) inhibitors in cancer chemotherapy[J]. Recent Pat Anticancer Drug Discov, 2006, 1(1): 39-53．
[62]
Curtin NJ. PARP inhibitors for cancer therapy[J]. Expert Rev Mol Med, 2005, 7(4): 1-20.
[63]
Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitiors[J]. Nat Rev Drug Discov, 2005, 4: 421-440.
[64]
Haddad M, Rhinn H, Bloquel C, et al. Antiinflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice[J]. Br J Pharmacol, 2006, 149: 23-30.
[65]
Hamby AM, Suh SW, Kauppinen TM, et al. Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after ischemia-reperfusion[J]. Stroke, 2007, 38: 632-636.
[66]
Jones P. Development of MK-4827: A novel oral poly(ADP-ribose)polymerase(PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors[C]//238th National Meeting of the American Chemical Society, 2009.
[67]
Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor[J]. Mol Cancer Ther, 2003, 2: 371-382.
[68]
Andersson Y, Bergstrom M, Langstrom B. Synthesis of 11C-labelled benzamide compounds as potential tracers for poly(ADP-ribose) synthetase[J]. Appl Radiat Isot, 1994, 45: 707-714.
[69]
Miyake Y, Kuge Y, Shimadzu H, et al. Biodistribution of 3,4-dihydro-5-[11C]methoxy-1(2H)-isoquinolinone, a potential PET tracer for poly(ADP-ribose) synthetase[J]. Nuclear Medicine & Biology, 2000, 27: 701-705.
[70]
Tu Zhude, Chu Wenhua, Zhang Jun, et al. Synthesis and in vivo evaluation of [11C]PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis[J]. Nuclear Medicine & Biology, 2005, 32: 437-443.
[71]
Riss PJ, Soskic V, Schrattenholz A, et al. Synthesis and radiosynthesis of N5-[18F]fluoroethyl-pirenzepine and its metabolite N5-[18F]fluoroethyl-LS 75[J]. J Label Compd Radiopharm, 2009, 52: 576-579.
